Glucarpidase

Brand names: Voraxaze · Active ingredient: Glucarpidase

In short: VORAXAZE is indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific fo

Forms & strengthsFor Injection: 1,000 Units as a white lyophilized powder in a single-dose vial for reconstitution.
LabelBTG International Inc.
Label updatedDec 02, 2024

What is Glucarpidase used for?

VORAXAZE is indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function.

Limitations of Use:VORAXAZE is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate

.

Glucarpidase dosage

The recommended dosage of VORAXAZE is 50 Units per kilogram (kg) as a single intravenous injection administered over 5 minutes. Flush intravenous line before and after administration.

When administering VORAXAZE concomitantly with leucovorin, administer leucovorin at least 2 hours before or 2 hours after the VORAXAZE dose

.

For the first 48 hours after a dose of VORAXAZE:

Administer the same leucovorin dosage given prior to the VORAXAZE dose.

Beyond 48 hours after a dose of VORAXAZE:

Determine the leucovorin dosage based on the measured methotrexate concentration. Do not discontinue leucovorin based on the determination of a single methotrexate concentration below the leucovorin rescue threshold.

Continue leucovorin until the methotrexate concentration has been maintained below the leucovorin rescue threshold for a minimum of 3 days.

Continue intravenous hydration and urinary alkalinization as indicated.

When measuring methotrexate concentrations following a VORAXAZE dose, a chromatographic method is preferred over an immunoassay

.

Reconstitute the contents of the vial with 1 mL of 0.9% Sodium Chloride Injection, USP.

Roll and tilt the vial gently to mix. Do not shake.

Inspect the vial and discard VORAXAZE if the solution is not clear, colorless, and free of particulate matter.

Use reconstituted VORAXAZE immediately or store under refrigeration at 36° to 46°F (2° to 8°C) for up to 4 hours if not used immediately. VORAXAZE contains no preservative and is supplied as a single-dose vial. Discard any unused product.

How to take Glucarpidase — instructions & advice from the label

Serious Hypersensitivity Reactions

Inform patients that hypersensitivity reactions, including potentially serious reactions, may occur following a dose of VORAXAZE and to immediately report any signs and symptoms of infusion reactions

.

Administration

Inform patients of the importance of continued monitoring of plasma methotrexate concentration and renal function at the appropriate times after discharge from the hospital

.

Manufactured and distributed by:

BTG International Inc.

West Conshohocken, PA 19428

U.S. license 1861

VORAXAZE

®is a registered trademark of Protherics Medicines Development

Ltd. BTG and the BTG roundel logo are registered trademarks of BTG

International Ltd.

P21011D

Warnings & precautions

Do not take this medicine if: None.

Serious hypersensitivity reactions occurred in less than 1% of patients .

DAMPA (4-deoxy-4-amino-N

10- methylpteroic acid), an inactive metabolite of methotrexate formed following VORAXAZE administration, interferes with the measurement of methotrexate concentration using immunoassays. This interference results in an overestimation of the methotrexate concentration. Based on the half-life of DAMPA (about 9 hours), VORAXAZE may interfere with the measurement of methotrexate concentration for up to 48 hours following a VORAXAZE dose

.

When measuring methotrexate concentration following a VORAXAZE dose, a chromatographic method is preferred over an immunoassay.

Glucarpidase side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Serious Hypersensitivity Reactions

[Warnings and Precautions (

5.1)].

Because clinical trials are conducted under controlled but widely varying conditions, adverse reaction rates observed in clinical trials of VORAXAZE cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.

The evaluation of adverse reactions in patients who received VORAXAZE was confounded, because patients had toxic plasma methotrexate concentration due to prolonged methotrexate clearance, which is associated with myelosuppression, mucositis, acute hepatitis, and renal dysfunction and failure.

The safety of VORAXAZE is based on data from 290 patients who were enrolled in Study 1 or Study 2, two single-arm, open-label, multicenter studies conducted in patients who had markedly delayed methotrexate clearance due to impaired renal function. Patients with osteosarcoma were eligible for these studies if the plasma methotrexate concentration was >50 µmol/L at 24 hours, >5 µmol/L at 48 hours, or >2 standard deviations above the mean methotrexate elimination curve at least 12 hours after methotrexate administration; and there was a ≥2-fold increase in serum creatinine above baseline. …

Drug interactions

VORAXAZE can decrease leucovorin concentration, which may decrease the effect of leucovorin rescue unless leucovorin is dosed as recommended

.

VORAXAZE may also reduce the concentrations other folate analogs or folate analog metabolic inhibitors.

DAMPA (4-deoxy-4-amino-N10- methylpteroic acid), an inactive metabolite of methotrexate formed following VORAXAZE administration, interferes with the measurement of methotrexate concentration using immunoassays. This interference results in an overestimation of the methotrexate concentration. Based on the half-life of DAMPA, VORAXAZE may interfere with the measurement of methotrexate concentrations for approximately 48 hours following a VORAXAZE dose

.

When measuring methotrexate concentration following a VORAXAZE dose, a chromatographic method is preferred over an immunoassay.

About this medicine

Glucarpidase is a carboxypeptidase produced by recombinant DNA technology in genetically modified

Escherichia coli.Glucarpidase is a 390-amino acid homodimer protein with a molecular weight of 83 kDa. Each potency Unit corresponds to the enzymatic cleavage of 1 µmol/L of methotrexate per minute at 37°C.

VORAXAZE (glucarpidase) for injection, for intravenous use is supplied as a sterile, preservative-free, white lyophilized powder in single-dose vials. Each vial contains 1,000 Units of glucarpidase, lactose monohydrate (10 mg), Tris-HCl (0.6 mg) and zinc acetate dihydrate (0.002 mg).

How it works: Glucarpidase is a recombinant bacterial enzyme that hydrolyzes the carboxyl- terminal glutamate residue from folic acid and classical antifolates such as methotrexate. Glucarpidase converts methotrexate to its inactive metabolites 4-deoxy-4-amino-N 10- methylpteroic acid (DAMPA) and glutamate. VORAXAZE provides an alternate non-renal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID acaef5a6-b740-40e3-8ffe-74a75c74745c. Read the full official label on DailyMed.